Company news

Alligator Bioscience AB news in 2025

Alligator Bioscience AB's news releases, calls and decks from 2025, newest first.

View company

Alligator Bioscience Announces Preliminary Outcome in Rights Issue

December 19, 2025

Alligator Bioscience Comments on Henlius Receiving Regulatory Approval in China to Initiate Phase 2/3 Trials of HLX22 in HER2-Positive Breast Cancer

December 9, 2025

Alligator Publishes Supplement Prospectus

December 3, 2025

Alligator Bioscience Publishes Financial Calendar for 2026

December 3, 2025

Alligator Bioscience Enters into Additional Subscription Undertakings and Top Guarantee Commitments for the Upcoming Rights Issue

December 1, 2025

Alligator Bioscience Announces Publication of REACtiVe-2 Phase 1 trial data in Nature Communications

December 1, 2025

Bulletin from The Extraordinary General Meeting in Alligator Bioscience AB

November 25, 2025

Alligator Bioscience Presents New Data on Mitazalimab and ATOR-4066 at SITC 40th Anniversary Annual Meeting

November 5, 2025

Nomination Committee Appointed in Respect of AGM 2026 in Alligator Bioscience AB

November 3, 2025

Alligator Bioscience AB Reports Financial Results for Q3 2025 and Provides a Business Update

October 23, 2025

Notice of Extraordinary General Meeting in Alligator Bioscience AB

October 22, 2025

Alligator Bioscience Carries Out a Rights Issue of Units of Approximately SEK 120 Million and Raises Bridge Loans

October 22, 2025

Alligator Bioscience Granted US Patent Covering ATOR-4066 Bispecific Antibody

October 21, 2025

Invitation to Alligator Bioscience's Earnings Call on 23 October 2025

October 16, 2025

REACtiVe-2 Phase 1 Data Featuring Mitazalimab Demonstrate Immune Activation in Metastatic Pancreatic Cancer - To be Presented at ESMO 2025

October 13, 2025

Alligator Announces Publication of OPTIMIZE-1 Biomarker Analysis in Cell Reports Medicine Supporting mitazalimab and mFOLFIRINOX in Metastatic Pancreatic Cancer

October 8, 2025

Alligator Bioscience Announces Acceptance of Two Abstracts at SITC 40th Anniversary Annual Meeting

October 6, 2025

Alligator Announces Final 30-Month OPTIMIZE-1 Results Highlighting the Potential of Mitazalimab in Metastatic Pancreatic Cancer

September 22, 2025

Alligator Bioscience AB Announces Final Outcome of Exercise of Warrants Series TO 13

September 17, 2025

Alligator Bioscience AB Announces Preliminary Outcome of Exercise of Warrants Series TO 13

September 16, 2025

Alligator to Present New Preclinical Results on ATOR-4066 at CICON25

September 12, 2025

Alligator Announces Publication in Cancer Immunology Research of Preclinical Data on ATOR-4066, a Tumor-Directed CD40×CEACAM5 Bispecific Antibody

September 10, 2025

Alligator Bioscience Has Renegotiated the Outstanding Loan From Fenja Capital and Received Subscription Intentions From Members of the Board of Directors and Management

September 8, 2025

Alligator Bioscience to present at BioStock's "Investing in Life Science" event

September 5, 2025

Alligator Announces Evaluation and Option Agreement Covering RUBY(TM) Antibody Format

September 2, 2025

Exercise Price Determined for the Exercise of Warrants Series TO 13 in Alligator Bioscience AB

August 27, 2025

Alligator Bioscience Provides Highlights from R&D Event 2025

August 20, 2025

Alligator Bioscience to Host Virtual R&D Day on 19 August 2025

August 14, 2025

Alligator Bioscience Announces Upcoming Presentation of REACtiVe-2 Phase 1 Data at ESMO Congress 2025

July 25, 2025

Alligator Bioscience Comments on Henlius Dosing First Patient in the US in Phase 3 Trial of HLX22 in Gastric Cancer

July 14, 2025

Alligator Bioscience AB Reports Financial Results for Q2 2025 and Provides a Business Update

July 10, 2025

Alligator to Present 24-Month OPTIMIZE-1 Data at ESMO GI 2025

July 1, 2025

Alligator Receives Positive Scientific Advice from EMA on Phase 3 Trial of Mitazalimab

June 17, 2025

Alligator Bioscience Receives FDA Endorsement of Mitazalimab Phase 3 Dose for Pancreatic Cancer

June 13, 2025

Biomarker Data from Alligator Bioscience’s OPTIMIZE-1 Trial Presented at ASCO 2025 Annual Meeting

June 3, 2025

Alligator Bioscience AB Carries Out Directed Issues to Guarantors in Connection with Exercise of Warrants Series TO 12

May 26, 2025

Alligator Bioscience Announces European Orphan Drug Designation for HLX22 in Gastric Cancer

May 26, 2025

Alligator Bioscience Presents OPTIMIZE-1 Biomarker Data at ASCO 2025 Annual Meeting

May 23, 2025

Alligator Bioscience AB Announces Final Outcome of Exercise of Warrants Series TO 12

May 21, 2025

Alligator Bioscience Announces Paediatric Study Waiver for Mitazalimab Granted by the European Medicines Agency

May 20, 2025

Alligator Bioscience AB Announces Preliminary Outcome of Exercise of Warrants Series TO 12

May 20, 2025

Alligator Bioscience to Attend ASCO 2025 Annual Meeting

May 12, 2025

Alligator Bioscience Announces that 85% of the Warrant Programme TO 12 has Been Secured and that the Outstanding Loan has Been Renegotiated

May 9, 2025

Alligator Bioscience Completes Phase 3 GMP Manufacturing of Mitazalimab, Remains on Track for Trial Initiation with Partner

May 9, 2025

Alligator Bioscience Updates Dividend Policy

May 8, 2025

Bulletin from the Annual General Meeting in Alligator Bioscience AB on 7 May 2025

May 7, 2025

Exercise Price Determined for the Exercise of Warrants Series TO 12 in Alligator Bioscience AB

April 28, 2025

Alligator Bioscience AB Reports Financial Results for Q1 2025 and Provides a Business Update

April 24, 2025

Alligator Bioscience Announces Initiation of HLX22 Phase 2 Trial in Breast Cancer by Shanghai Henlius Biotech, Inc.

April 23, 2025

Calls in 2025

Decks in 2025